IL228158A - History of 7,6-Dihydro-pyrazolo [5,1- a] Pirazine-4-Illamine used as an inhibitor of thescretase - Google Patents

History of 7,6-Dihydro-pyrazolo [5,1- a] Pirazine-4-Illamine used as an inhibitor of thescretase

Info

Publication number
IL228158A
IL228158A IL228158A IL22815813A IL228158A IL 228158 A IL228158 A IL 228158A IL 228158 A IL228158 A IL 228158A IL 22815813 A IL22815813 A IL 22815813A IL 228158 A IL228158 A IL 228158A
Authority
IL
Israel
Prior art keywords
mixture
mmol
vacuo
compound
acid
Prior art date
Application number
IL228158A
Other languages
English (en)
Hebrew (he)
Other versions
IL228158A0 (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL228158A0 publication Critical patent/IL228158A0/en
Publication of IL228158A publication Critical patent/IL228158A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL228158A 2011-03-01 2013-08-28 History of 7,6-Dihydro-pyrazolo [5,1- a] Pirazine-4-Illamine used as an inhibitor of thescretase IL228158A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11156463 2011-03-01
PCT/EP2012/053455 WO2012117027A1 (en) 2011-03-01 2012-02-29 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)

Publications (2)

Publication Number Publication Date
IL228158A0 IL228158A0 (en) 2013-11-25
IL228158A true IL228158A (en) 2016-07-31

Family

ID=45808845

Family Applications (1)

Application Number Title Priority Date Filing Date
IL228158A IL228158A (en) 2011-03-01 2013-08-28 History of 7,6-Dihydro-pyrazolo [5,1- a] Pirazine-4-Illamine used as an inhibitor of thescretase

Country Status (27)

Country Link
US (1) US9346811B2 (enExample)
EP (1) EP2681219B1 (enExample)
JP (1) JP5853033B2 (enExample)
KR (1) KR102012671B1 (enExample)
CN (1) CN103415519B (enExample)
AU (1) AU2012222394B2 (enExample)
BR (1) BR112013022039A2 (enExample)
CA (1) CA2824360C (enExample)
CL (1) CL2013002486A1 (enExample)
CO (1) CO6751282A2 (enExample)
CY (1) CY1117663T1 (enExample)
DK (1) DK2681219T3 (enExample)
EA (1) EA022649B1 (enExample)
ES (1) ES2558779T3 (enExample)
HR (1) HRP20160030T1 (enExample)
HU (1) HUE026338T2 (enExample)
IL (1) IL228158A (enExample)
MX (1) MX338333B (enExample)
MY (1) MY161407A (enExample)
PH (1) PH12013501807A1 (enExample)
PL (1) PL2681219T3 (enExample)
PT (1) PT2681219E (enExample)
SG (1) SG192963A1 (enExample)
SI (1) SI2681219T1 (enExample)
UA (1) UA109800C2 (enExample)
WO (1) WO2012117027A1 (enExample)
ZA (1) ZA201306545B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2476027T3 (es) 2005-10-25 2014-07-11 Shionogi & Co., Ltd. Derivados de aminodihidrotriazina
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
KR20100017255A (ko) 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
MX2010013256A (es) 2008-06-13 2010-12-21 Shionogi & Co Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa.
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
EP2580200B1 (en) 2010-06-09 2016-09-14 Janssen Pharmaceutica, N.V. 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
CN103403007B (zh) 2010-12-22 2015-12-09 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5,6-二氢-咪唑并[1,2-a]吡嗪-8-基胺衍生物
BR112013022039A2 (pt) 2011-03-01 2016-11-29 Janssen Pharmaceutica Nv derivados 6,7-di-hidro-pirazol[1,5-a]pirazin-4-ilamina úteis como inibidores de beta-secretase (bace)
SI3447061T1 (sl) 2011-03-01 2022-02-28 NuCana plc Farmacevtska formulacija, ki obsega fosforamidni derivat 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka
KR102012675B1 (ko) 2011-03-09 2019-08-21 얀센 파마슈티카 엔.브이. 베타-세크레타제(BACE)의 억제제로서 유용한 3,4-디하이드로-피롤로[1,2-a]피라진-1-일아민 유도체
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
CA2911690C (en) * 2013-06-12 2021-08-24 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
AU2014280125B2 (en) * 2013-06-12 2018-03-15 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE)
BR112015030498A2 (pt) 2013-06-12 2017-07-25 Janssen Pharmaceutica Nv derivados 4-amino-6-fenil-5,6-di-hidroimidazo[1,5-a]pirazin-3(2h)-ona como inibidores de beta-secretase (bace)
WO2016096979A1 (en) 2014-12-18 2016-06-23 Janssen Pharmaceutica Nv 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
EP3909583A4 (en) 2019-01-11 2022-08-17 Shionogi & Co., Ltd DIHYDROPYRAZOLOPYRAZINONE DERIVATIVES WITH MGAT2 INHIBITORY ACTIVITY
KR20250022711A (ko) * 2022-06-13 2025-02-17 시오노기 앤드 컴파니, 리미티드 다이하이드로피리딘온 유도체 또는 그 용매화물의 결정

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188389A (en) 1978-11-03 1980-02-12 Ayerst Mckenna & Harrison, Inc. 1,2,3,4-Tetrahydropyrrolo(1,2-A)pyrazines
TW224974B (enExample) 1991-07-02 1994-06-11 Hoffmann La Roche
WO2003089434A2 (en) 2002-04-19 2003-10-30 Cellular Genomics, Inc. IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF
AU2003272476B2 (en) 2002-09-23 2007-07-05 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
WO2004092177A1 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
JP2007533641A (ja) 2003-10-15 2007-11-22 ターガセプト，インコーポレイテッド 疼痛緩和および中枢神経系障害治療のためのアザビシクロ化合物
JP2007533741A (ja) 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー Ｂａｃｅ阻害剤
TW200602045A (en) 2004-06-16 2006-01-16 Wyeth Corp Amino-5, 5-diphenylimidazolone derivatives for the inhibition of β-secretase
SV2006002232A (es) 2004-09-21 2006-05-25 Lilly Co Eli Inhibidores bace ref. x-16940
CA2593515A1 (en) 2005-01-14 2006-07-20 Wyeth Amino-imidazolones for the inhibition of beta-secretase
US20070005404A1 (en) 2005-06-09 2007-01-04 Drive Diagnostics Ltd. System and method for providing driving insurance
CA2610828A1 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
AU2006266167A1 (en) 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
ES2476027T3 (es) 2005-10-25 2014-07-11 Shionogi & Co., Ltd. Derivados de aminodihidrotriazina
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
US20090099217A1 (en) 2006-04-05 2009-04-16 Astex Therapeutics Ltd. 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies
GB2443654A (en) 2006-05-30 2008-05-14 Matthew Emmerson Allen System for detecting and testing drivers who show abnormal driving behaviour.
TW200815443A (en) * 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
CN101501040A (zh) * 2006-06-14 2009-08-05 阿斯利康(瑞典)有限公司 氨基-咪唑啉以及它们作为治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物的用途
US20080051420A1 (en) * 2006-06-14 2008-02-28 Astrazeneca Ab New Compounds 317
KR20100017255A (ko) 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
EP2217592A1 (en) 2007-10-30 2010-08-18 Arena Pharmaceuticals, Inc. Biphenyl derivatives as modulators of the histamine-h3 receptor useful for the treatment of disorders related thereto
RU2497821C2 (ru) 2008-01-28 2013-11-10 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННОГО-ТИО (ИЛИ -ОКСО-)-2-АМИНО-ХИНОЛИНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ (BACE)
EP2252617A1 (en) 2008-02-13 2010-11-24 CGI Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2011002409A1 (en) * 2009-07-02 2011-01-06 Astrazeneca Ab 5h-pyrrolo[3,4-£>]pyrazin-7-amine derivatives inhibitors of beta-secretase
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
EP2500344A4 (en) 2009-11-13 2013-05-01 Shionogi & Co AMINOTHIAZIN OR AMINOOXAZINE DERIVATIVES WITH AN AMINO TERMINATION
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
WO2011077726A1 (ja) 2009-12-24 2011-06-30 塩野義製薬株式会社 ４－アミノ－１，３－チアジンまたはオキサジン誘導体
BR112012015916A2 (pt) 2009-12-31 2017-04-25 Novartis Ag derivados de pirazina e seu uso no tratamento de distúrbios neurológicos
EP2580200B1 (en) 2010-06-09 2016-09-14 Janssen Pharmaceutica, N.V. 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
CN103403007B (zh) 2010-12-22 2015-12-09 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5,6-二氢-咪唑并[1,2-a]吡嗪-8-基胺衍生物
US9242943B2 (en) 2011-01-18 2016-01-26 Siena Biotech S.P.A. 1,4 oxazines as BACE1 and/or BACE2 inhibitors
BR112013022039A2 (pt) 2011-03-01 2016-11-29 Janssen Pharmaceutica Nv derivados 6,7-di-hidro-pirazol[1,5-a]pirazin-4-ilamina úteis como inibidores de beta-secretase (bace)
KR102012675B1 (ko) 2011-03-09 2019-08-21 얀센 파마슈티카 엔.브이. 베타-세크레타제(BACE)의 억제제로서 유용한 3,4-디하이드로-피롤로[1,2-a]피라진-1-일아민 유도체
WO2013054291A1 (en) 2011-10-13 2013-04-18 Novartis Ag Novel oxazine derivatives and their use in the treatment of disease

Also Published As

Publication number Publication date
CO6751282A2 (es) 2013-09-16
WO2012117027A1 (en) 2012-09-07
US9346811B2 (en) 2016-05-24
MX2013010040A (es) 2013-11-04
PL2681219T3 (pl) 2016-03-31
EA201391251A1 (ru) 2014-01-30
BR112013022039A2 (pt) 2016-11-29
SI2681219T1 (sl) 2016-02-29
NZ614551A (en) 2014-06-27
PH12013501807A1 (en) 2015-09-30
CN103415519A (zh) 2013-11-27
UA109800C2 (xx) 2015-10-12
IL228158A0 (en) 2013-11-25
AU2012222394B2 (en) 2016-06-16
KR20140010052A (ko) 2014-01-23
US20140005200A1 (en) 2014-01-02
EP2681219A1 (en) 2014-01-08
CA2824360A1 (en) 2012-09-07
SG192963A1 (en) 2013-09-30
CN103415519B (zh) 2016-03-02
AU2012222394A1 (en) 2013-07-25
MX338333B (es) 2016-04-11
JP2014506907A (ja) 2014-03-20
CY1117663T1 (el) 2017-05-17
HUE026338T2 (en) 2016-05-30
HRP20160030T1 (hr) 2016-02-12
KR102012671B1 (ko) 2019-08-21
DK2681219T3 (en) 2016-01-18
PT2681219E (pt) 2016-02-10
JP5853033B2 (ja) 2016-02-09
CA2824360C (en) 2020-01-14
CL2013002486A1 (es) 2014-02-21
MY161407A (en) 2017-04-14
ES2558779T3 (es) 2016-02-08
EP2681219B1 (en) 2015-10-28
HK1188784A1 (zh) 2014-05-16
EA022649B1 (ru) 2016-02-29
ZA201306545B (en) 2015-03-25

Similar Documents

Publication Publication Date Title
AU2012222394B2 (en) 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
CA2819175C (en) 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace)
AU2012224632B2 (en) 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
EP2619207B1 (en) 4,7-Dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta secretase (BACE)
NZ614551B2 (en) 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
HK1189221B (en) 5,6-dihydro-imidazo[1,2-a] pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed